Q1 results this week: Bharti Airtel, Trent, BSE, Adani Ports, and LIC among 128 companies to announce earnings
DLF
,
Adani Ports
,
Bharti Airtel
,
Lupin
,
Bajaj Auto
,
BHEL
,
Trent
,
BSE
, Life Insurance Corporation (
LIC
),
Sun TV Network
, Titan, and
Tata Motors
.
Here's the day-wise list of key earnings to watch:
Explore courses from Top Institutes in
Please select course:
Select a Course Category
Operations Management
Data Analytics
Data Science
MCA
MBA
Design Thinking
healthcare
Others
Data Science
others
CXO
Technology
Cybersecurity
Management
Digital Marketing
Healthcare
Leadership
Public Policy
Artificial Intelligence
Degree
Finance
Project Management
PGDM
Product Management
Skills you'll gain:
Quality Management & Lean Six Sigma
Analytical Tools
Supply Chain Management & Strategies
Service Operations Management
Duration:
10 Months
IIM Lucknow
IIML Executive Programme in Strategic Operations Management & Supply Chain Analytics
Starts on
Jan 27, 2024
Get Details
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Colombia: New Container Houses (Prices May Surprise You)
Container House | Search ads
Search Now
Undo
4th August
Aditya Birla Capital, Akzo Nobel India, Aurobindo Pharma, Bosch, DLF, Escorts Kubota, Godfrey Phillips India, Inox India, Kansai Nerolac Paints, Marico, Shree Cement, Sona BLW Precision Forgings, Sumitomo Chemical India, Tata Investment Corporation, TBO Tek, and Triveni Turbine.
5th August
Adani Ports and Special Economic Zone, Alembic Pharmaceuticals, Berger Paints India, Bharti Airtel, Bharti Hexacom, BLS International Services, Britannia Industries, Castrol India, CCL Products (India), Container Corporation of India, EIH, Eris Lifesciences, Exide Industries, Gland Pharma, Godawari Power and Ispat, Gujarat Fluorochemicals, Gujarat Gas, Jindal Saw, Lupin, NCC, Prestige Estates Projects, Sheela Foam, and Torrent Power.
6th August
Bajaj Auto, Bajaj Holdings & Investment, Bayer CropScience, Bharat Forge, Bharat Heavy Electricals, Blue Star, Cera Sanitaryware, Divi's Laboratories, E.I.D. - Parry (India), Fortis Healthcare, Godrej Agrovet, Gujarat Narmada Valley Fertilizers & Chemicals, Hero MotoCorp, Housing & Urban Development Corporation, Ircon International, Jindal Stainless, Jyoti CNC Automation, K.P.R. Mill, Kirloskar Oil Engines, Krishna Institute of Medical Sciences, Pidilite Industries, Power Finance Corporation, PVR Inox, Raymond Lifestyle, Raymond, Rites, SKF India, Trent, UNO Minda.
Live Events
7th August
3M India, Apollo Tyres, Biocon, Birlasoft, BSE, Caplin Point Laboratories, Carborundum Universal, Century Plyboards (India), Crompton Greaves Consumer Electricals, Cummins India, Data Patterns (India), Emcure Pharmaceuticals, General Insurance Corporation of India, Global Health, Godrej Consumer Products, Gujarat State Fertilizers & Chemicals, Hindustan Petroleum Corporation, Kalpataru Projects International, Kalyan Jewellers India, Life Insurance Corporation of India, Linde India, Max Financial Services, Metro Brands, Metropolis Healthcare, MMTC, National Aluminium Company, NBCC (India), NLC India, Page Industries, Sai Life Sciences, Schneider Electric Infrastructure, Shree Renuka Sugars, Solar Industries India, Sun TV Network, The Ramco Cements, Titan Company, Varroc Engineering.
8th August
Action Construction Equipment, Afcons Infrastructure, Cholamandalam Financial Holdings, DOMS Industries, Fine Organic Industries, Garden Reach Shipbuilders & Engineers, Garware Technical Fibres, Grasim Industries, IFCI, Info Edge (India), Lemon Tree Hotels, Manappuram Finance, PG Electroplast, Poly Medicure, PTC Industries, RHI Magnesita India, Shipping Corporation Of India, Star Cement, State Bank Of India, Tata Motors, Voltas, Wockhardt.
9th August
HBL Engineering
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
7 minutes ago
- Business Standard
Lupin shares advance 5% after Q1 results; should you buy in?
Shares of Lupin gained nearly 5 per cent on Thursday as analysts remained bullish after the firm posted a 52 per cent year-on-year increase in net profit in the first quarter of the current financial year (Q1FY26) The pharma major's stock rose as much as 4.65 per cent during the day to ₹1,937.9 per share, the biggest intraday rise since April 28 this year. The stock pared gains to trade 3.8 per cent higher at ₹1,919 apiece, compared to a 0.32 per cent decline in Nifty 50 as of 9:57 AM. Shares of the company snapped a two-day losing streak and currently trade at 5.9 times the average 30-day trading volume, according to Bloomberg. The counter has fallen 18 per cent this year, compared to a 3.6 per cent advance in the benchmark Nifty 50. Lupin has a total market capitalisation of ₹88,332.65 crore. Lupin Q1 results The drug maker reported a profit after tax (PAT) of ₹1,221 crore in the April-June quarter, marking an increase of 72 per cent year-on-year (Y-o-Y). Revenue rose to ₹6,164 crore in the first quarter as against ₹5,514 crore in the year-ago period. The company said its sales in the US stood at ₹2,404 crore in the June quarter, registering a growth of 24 per cent as compared to ₹1,934 crore in the year-ago period. India sales for Q1 FY26 stood at ₹2,089 crore, up 8 per cent from ₹1,938 crore. "We continue to build strong business momentum, anchored by a robust product portfolio, improved efficiencies, and effective use of assets and investments," Managing Director Nilesh Gupta said. "As we begin the year, our sharpened focus on compliance, innovation, and technology positions us to further unlock sustainable growth," he added. Analysts on Lupin Q1 results Antique Stock Broking noted that Lupin delivered a strong first-quarter performance for FY26. Ebitda rose 28 per cent Y-o-Y despite a 38 per cent increase in R&D expenses. The quarter marked the launch of Tolvaptan (gJynarque) under sole FTF exclusivity in the US, boosting US sales to $282 million, it said, adding that the base US business saw single-digit price erosion. A further ramp-up is expected in the second quarter, analysts said. It maintained a 'Buy' rating on the stock with a revised target of ₹2,450 per share (earlier ₹2,395). Systematix Institutional Equities said that while revenue and Ebitda came in below expectations, net profit was in line. The revenue and Ebitda miss was primarily due to lower-than-expected US sales, it noted. The brokerage has revised its estimates to reflect a higher contribution from generic Mirabegron over the year. Systematix maintains a 'Hold' rating on Lupin with a target price of ₹2,050. Lupin's superior performance was driven by 180-day exclusivity in tolvaptan and continued running in gSpiriva and gMyrbetriq, according to analysts at Nuvama Institutional Equities. FY26 is a strong year for Lupin with further launches of glucagon and liraglutide over the next few months, it said. They retained 'Buy' with a target price of ₹2,340 per share.
Time of India
10 hours ago
- Time of India
Indian pharma on alert as US mulls higher drug tariffs
Indian drug makers are weighing the possible fallout of additional reciprocal tariffs imposed by the US in response to the country's oil purchases from Russia. Earlier, the Trump administration had imposed a 25% tariff effective August 1 but it had spared pharmaceutical products from India. Experts said the tariffs are held back on pharma imports due to the ongoing investigation by the US government related to imports of pharmaceutical products and national security under Section 232 of the Trade Expansion Act, 1962. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Sources in the pharma industry said the same situation may prevail but they said there is an air of uncertainty given the frequent changes in the structure, prompting drug makers to look at mitigation strategies. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Orthopedic Knee Surgeon: Suffering From Pain After Age 50? Do This Every Morning Wellnee Undo Over its first quarter earnings call with investors on Wednesday, Lupin CEO Vinita Gupta said, "It is hard to predict where this (tariff) lands". But she added the company has considered price flexibility to offset the impact of tariffs. She also noted the possibility of a tech transfer into the US to cut the tariff impact. Alluding to President Trump's most recent hints at a 10-15% tariff on pharma imports, she said, "I think it will be fairly manageable. In any case the question is whether it is 25% or 150% or 200% kind of numbers that are being floated". Live Events Company executives however noted that the US government will be very conscious about the measures they take because it is about access to medicine and could impact them significantly. Indian Pharmaceutical Alliance secretary general Sudarshan Jain said, "The recent executive order by the US administration excludes the pharmaceutical sector from immediate tariff imposition. The sector is being reviewed under Section 232 investigation". "Generic medicines are important for affordable healthcare in the US and typically operate on razor-thin margins. Ensuring their consistent availability is critical for patient care. India-US partnership is key to securing API supply chains and enhancing healthcare resilience," he said.
Mint
11 hours ago
- Mint
Mobile tariff design skewed in India; rich paying less: Airtel MD
New Delhi, Aug 6 (PTI) Bharti Airtel sees an opportunity in raising tariffs for data services as it feels that the rich are paying less and the poor are not required to pay anymore, a senior official of the company said. A customer needs to pay ₹ 199 for a month-long connection which comes with unlimited local, STD, roaming calls and a 2GB data limit. By paying ₹ 100 more, a subscriber on Airtel can get 1 GB data per day and it goes up to 3 GB data per day with plans starting from ₹ 449 onwards. "The architecture of pricing in India is quite skewed. At the entry level itself or just above the entry level, you get so much data allowance, calling and messaging, that you really don't have any reason to upgrade. It's just an unfortunate situation where people who can afford to pay, the rich, are paying less and the poor, you know, we don't need to charge the poor anymore," Bharti Airtel Vice-Chairman and MD, Gopal Vittal said. He was replying to a question on tariffs during the company's earnings call for the first quarter of the current fiscal. Bharti Airtel has posted a 43 per cent year-on-year increase in its consolidated profit to ₹ 5,947.9 crore in the quarter ended June 2025 mainly on account of an increase in customer base. Vittal said if India had a more sensible pricing architecture like Indonesia, ARPU (average revenue per user) would have been substantially higher than where the country's telecom industry is at present without any pain to customers at the low end. As per UK-based data price information platform average data price in India was around 16 cents while in Indonesia it was around 28 cents in 2023. Bharti Airtel India operations average revenue per user (ARPU), a key matrix to determine a telecom operator's growth, in India increased to ₹ 250 during the June 2025 quarter under review compared to ₹ 211 in the same period a year ago. The mobile data consumption on Airtel's India network increased by 13.4 per cent to 26.9 GB per customer per month. The customer base of Airtel's Home Services segment, which includes fixed broadband services, grew 37.7 per cent on YoY basis to 1.09 crore but the ARPU in the segment declined by 6.1 per cent to ₹ 537 in June 2025 quarter. Consolidated revenue from operations of Bharti Airtel increased by 28.4 per cent to ₹ 49,463 crore during the reporting quarter from ₹ 38,506.4 crore in the June quarter of the last year.
